You are here:
tadalafil (Adcirca)
Advice
in the absence of a submission from the holder of the marketing authorisation
tadalafil (Adcirca ®) is not recommended for use within NHS Scotland.
Indication under review: for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Drug Details
| Drug Name: | tadalafil (Adcirca) |
|---|---|
| SMC Drug ID: | 710/11 |
| Manufacturer: | Lilly UK |
| Indication: | For the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. |
| BNF Category: | |
| Sub Category: | 2.5 Hypertension and heart failure |
| Submission Type: | Non submission |
| Status: | Not Recommended |
| Date Advice Published: | 9 May 2011 |